Qilian International Holding Group Limited (QLI) News

Qilian International Holding Group Limited (QLI): $1.99

0.01 (+0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add QLI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 490

in industry

Filter QLI News Items

QLI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest QLI News From Around the Web

Below are the latest news stories about Qilian International Holding Group Ltd that investors may wish to consider to help them evaluate QLI as an investment opportunity.

Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ended September 30, 2021.

Yahoo | February 11, 2022

Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administ

Yahoo | January 19, 2022

Qilian International Holding Group Limited Releases 2022 Chairman Letter

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Company's board of directors.

Yahoo | January 11, 2022

Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), have been included in the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province (the "List"). The List selects key medicines and medical dev

Yahoo | November 23, 2021

Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that the Company recently started, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), developing a new drug, Vitacoenzyme (the "Drug"), that aims to prevent gastric cancer. Currently, Gansu QLS is in the process of selecting and cultivating fungal strain. The Drug is expected to be on the market within three years.

Yahoo | November 15, 2021

Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Company donated Gan Di Xin®, its self-developed antitussive and expectorant medicine, and 75% alcohol disinfectant, with an aggregate value of more than RMB500,000 to the government of Suzhou District, Jiuquan City to help control the spread of local C

Yahoo | November 1, 2021

Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer production facility. As a result, the Company's annual production capacity of organic fertilizers has increased to 30,000 tons. After the Expansion is fully complete, the Company's annual production capacity of organic fertilizers is expected to reach 50,00

Yahoo | October 26, 2021

Is Qilian International Holding Group Limited's (NASDAQ:QLI) Recent Price Movement Underpinned By Its Weak Fundamentals?

It is hard to get excited after looking at Qilian International Holding Group's (NASDAQ:QLI) recent performance, when...

Yahoo | October 25, 2021

Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt

Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "Gansu QLS"), it has received Certificate of a Pharmaceutical Product (the "Export Certificate") from Gansu Province Drug Administration, which approves the export of its Qilian Shan® Oxytetracycline APIs (Active Pharmaceutical Ingredients) (the "API")

Yahoo | October 13, 2021

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021

Jiuquan, China, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, “We are pleased with our financial results for the first six months of fiscal year 2021. Our revenue increased by 8% to $29.9 millio

Yahoo | September 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4796 seconds.